Molecular Templates (MTEM) Gets a Buy Rating from Oppenheimer
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Molecular Templates (MTEM) today and set a price target of $20.00. The company’s shares closed last Wednesday at $10.35.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 27.5% and a 50.2% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.
Molecular Templates has an analyst consensus of Strong Buy, with a price target consensus of $20.33.
See today’s analyst top recommended stocks >>
Based on Molecular Templates’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.91 million and GAAP net loss of $31.23 million. In comparison, last year the company earned revenue of $5.45 million and had a GAAP net loss of $9.15 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MTEM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Molecular Templates, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. Molecular Templates was founded on October 17, 2001 and is headquartered in Austin, TX.